Teva Pharmaceutical Industries Limited American DE (NYSE:TEVA) Can’t Be Less Risky. Short Interest Decreased

July 14, 2018 - By Robert Crowder

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

The stock of Teva Pharmaceutical Industries Limited American DE (NYSE:TEVA) registered a decrease of 3.69% in short interest. TEVA’s total short interest was 53.78 million shares in July as published by FINRA. Its down 3.69% from 55.84M shares, reported previously. With 9.00 million shares average volume, it will take short sellers 6 days to cover their TEVA’s short positions. The short interest to Teva Pharmaceutical Industries Limited American DE’s float is 5.71%.

The stock decreased 1.85% or $0.44 during the last trading session, reaching $23.29. About 9.08 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 22.74% since July 14, 2017 and is downtrending. It has underperformed by 35.31% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $23.72 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 19 analysts covering Teva Pharma (NYSE:TEVA), 5 have Buy rating, 3 Sell and 11 Hold. Therefore 26% are positive. Teva Pharma has $2800 highest and $13.0 lowest target. $19.68’s average target is -15.50% below currents $23.29 stock price. Teva Pharma had 32 analyst reports since January 16, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, May 7 by Mizuho. The firm has “Sell” rating by RBC Capital Markets given on Wednesday, January 24. Susquehanna maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Thursday, January 25. Susquehanna has “Buy” rating and $24.0 target. The rating was maintained by Mizuho on Friday, April 20 with “Buy”. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Sell” rating given on Friday, January 26 by Leerink Swann. The stock has “Buy” rating by Mizuho on Thursday, February 15. Morgan Stanley maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Monday, May 7 with “Equal-Weight” rating. The stock has “Hold” rating by Guggenheim on Tuesday, March 13. On Sunday, March 25 the stock rating was maintained by RBC Capital Markets with “Hold”. Citigroup maintained the stock with “Buy” rating in Thursday, May 31 report.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Investorplace.com which released: “4 Warren Buffett Stocks to Buy in Q2 Earnings” on July 13, 2018, also Streetinsider.com with their article: “Teva Pharma (TEVA) PT Raised to $25 at Cantor Fitzgerald” published on July 13, 2018, Fool.com published: “3 Warren Buffett Stocks Worth Buying Now” on July 14, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Seekingalpha.com and their article: “Teva: Shopping For Generic Bonds” published on July 03, 2018 as well as Businesswire.com‘s news article titled: “Teva to Report Second Quarter 2018 Financial Results on August 2, 2018” with publication date: July 11, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: